Answer the following questions to determine if your project is ready for Product Definition:
- Is the mechanism of action confirmed?
- Do you have supporting data to demonstrate that the target is validated to support the proposed mechanism of action?
Note: At the end of the R61 phase, investigators must exhibit successful completion of target identification and identification of lead compounds, and the R33 phase should result in preliminary in vitro and in vivo efficacy studies and identification of lead compounds. Lead optimization may be part of the R33 phase.